Nyxoah SA
NYXHAbout the company
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
2 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #3022 (Top 97.6%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-26 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-26 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 6✗ 22▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.7x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-116.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-116.7%, ROC=-989.5%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.7x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-89.5%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.7x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low105% of trailing low ($0.86)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-115.52%; #5460/6340 (top 86.1%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.6300; #2425/6449 (top 37.6%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-79.5%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.1285; #4181/5247 (top 79.7%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-89.49%; #4036/4519 (top 89.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-69.49%; #5645/6202 (top 91.0%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-82.0M✗LynchPositive and growingOperating Cash Flow$-81.0M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-58.22%, ROA=-76.04%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-89.5%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/7 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-211.7%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/7 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-82.0M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-89.49%; #4036/4519 (top 89.3%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 3✗ 10▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 11.5% vs Rev: 150.2%✓LynchInventory growth < Revenue growthEPS Growth Direction$-0.83 (2020) -> $-2.78 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/6 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth43.5%✓Ackman>= 5%Positive EPS Growth Frequency1/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 61.9% -> 63.1%, operating margin -1037.3% -> -833.2%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR168.2%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio1.25✗Graham>= 2.0ROIC (3-5 yr avg)-76.9%✗Buffett> 10%ROIC - WACC-86.9%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-989.5%✗Greenblatt> 25%Current Ratio Change YoY4.56 -> 1.25✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.03x -> 0.08x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities1.25✗Dreman> 1.5Return on Invested Capital-130.5%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-34.9%; FY2024: ROIC=-39.7%; FY2025: ROIC=-130.5%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -130.5%)✗SleepROIC > 12% in a majority of years - Verdicts0% pass✗ 15▾
Split decision: 14 FAIL · 2 NEUTRAL
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #3022✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2307/2370 (Top 97.3%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Profitability6% pass✓ 4✗ 31▾
15 of 16 flag NYXH's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/7 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/7 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-64.9%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-833.2% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-183.4%✗Lynch> 15%EBIT / Enterprise Value-116.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-116.7%, ROC=-989.5%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-76.04%✗PiotroskiROA > 0ROA Change YoY-37.40% -> -76.04% (delta: -38.64%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-58.22%, ROA=-76.04%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY65.7% -> 63.1%✗PiotroskiImproved YoYPre-Tax Income / Revenue-889.0%✗Dreman>= 8%Net Income / Shareholders' Equity-183.4%✗Dreman> 12%Margin of SafetyP/B=0.7x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-93.3% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/6 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-833.2%✗Ackman>= 15%Net Income / Shareholders Equity-183.4%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-1037.3% (2023) -> -833.2% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 61.9% -> 63.1%, operating margin -1037.3% -> -833.2%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-115.52%; #5460/6340 (top 86.1%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+5.34%; #3085/3702 (top 83.3%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-183.36%; #4846/5226 (top 92.7%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.2101; #4280/5884 (top 72.7%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/6 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage50% pass✓ 9✗ 6▾
6 of 12 pass — Graham, Buffett, Lynch +3 more object
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.03, IC: -7.2x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.03✓Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.25✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.03✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.03✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-7.2x, D/EBITDA=N/A (D&A unavailable)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.03✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0288; #835/4210 (top 19.8%)✓AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 15.0% of shares last year, 50.1% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
| Metric | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|
| Market Cap | $91.6Mcurrent | $404.2Mest. | $310.3Mest. | $139.3Mest. | $510.8Mest. |
| Revenue | $11.8M↑150% | $4.7M | $4.7M↑44% | $3.3M↑241% | $964.9K |
| Operating Income | -$98.1M↓60% | -$61.2M↓25% | -$48.9M↓41% | -$34.6M↓17% | -$29.7M |
| Net Income | -$105.8M↓72% | -$61.6M↓31% | -$46.9M↓41% | -$33.3M↓6% | -$31.3M |
| EPS (Diluted) | $-2.78↓48% | $-1.88↓12% | $-1.68↓30% | $-1.29↑2% | $-1.31 |
| Gross Margin | 63.1%↓4% | 65.7%↑6% | 61.9%↓1% | 62.7%↓3% | 64.4% |
| Operating Margin | -833.2%↑36% | -1300.8%↓25% | -1037.3%↑2% | -1053.8%↑66% | -3080.0% |
| ROE | -183.4%↓251% | -52.3%↓19% | -44.1%↓70% | -26.0%↓40% | -18.6% |
| Total Debt | $1.7M↓57% | $3.8M↓11% | $4.3M↑22% | $3.5M↓13% | $4.1M |
| Shareholders' Equity | $57.7M↓51% | $117.9M↑11% | $106.4M↓17% | $128.3M↓24% | $168.3M |
| Current Ratio | 1.25↓73% | 4.56↓4% | 4.73↓30% | 6.72↓44% | 12.10 |
| Debt / Equity | 0.03↓11% | 0.03↓20% | 0.04↑47% | 0.03↑14% | 0.02 |
| Operating Cash Flow | -$81.0M↓58% | -$51.2M↓5% | -$48.6M↓59% | -$30.7M↓7% | -$28.7M |
| Free Cash Flow | -$82.0M↓56% | -$52.4M↓2% | -$51.3M↓62% | -$31.6M↓4% | -$30.4M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
NYXH vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |